I
nflammatory bowel disease (IBD) is a disease of chronic intestinal inflammation punctuated by episodes of active disease and quiescent remission. IBD can be differentiated into ulcerative colitis and Crohn's disease (CD), which can follow markedly different clinical courses. The treatment of IBD focuses on effecting and maintaining remission at the level of the intestine and inducing symptomatic response. IBD therapeutic options have significantly improved over the past decade. Salicylates (5-ASAs) and other immunosuppressants such as azathioprine, methotrexate, and glucocorticoids as well as biologic treatments such as infliximab, adalimumab, golimumab, vedolizumab, and ustekinumab are important therapies for the optimal treatment of IBD.
Cytochrome P450 (CYP) 3A4 and the efflux transporter, Pglycoprotein (P-gp; adenosine triphosphate [ATP]-binding cassette protein B1, ABCB1), are thought to be involved in the disposition of approximately 40% to 50% of drugs in clinical use, including many used to treat IBD. [1] [2] [3] [4] Specifically, CYP3A4 has been shown capable of metabolizing glucocorticoids used in IBD, such as prednisone and budesonide. 2, 5 Similarly, P-gp has been implicated in the transport of methotrexate and azathioprine in addition to the glucocorticoids. 4, [6] [7] [8] [9] CYP3A4 is the most thoroughly investigated of the CYP3A isoforms. 1 CYP3A4 is expressed in predominantly in the liver and intestinal tract. 1 In the intestinal tract, CYP3A4 is found at the villous tip of individual enterocytes and aids in the catabolism of specific drug substrates. 10 P-gp, an efflux transporter protein that is a member of the ATP-binding cassette (ABC) superfamily, is encoded by the ABCB1 gene. 11 Similar to CYP3A4, this transporter is highly expressed in the liver and intestine, as well as other organs such as the kidney, and capillary endothelial cells that make up the blood-brain barrier. Interplay between CYP3A4 and P-gp is considered to be of particularly relevance to intestinal drug metabolism and transport. P-gp mRNA levels increase longitudinally along the intestine, from the stomach to colon. 12 The converse is true for CYP3A4, with the highest expression in the jejunum and ileum. 13, 14 Intestinal CYP3A4 and P-gp may act in concert in drug metabolism and play a key role in first-pass metabolism in addition to the role played by hepatic CYP3A4 and P-gp. P-gp bound to the cell membrane of enterocytes may regulate the exposure of specific drugs to metabolism by CYP3A4 by an active "counter transport" mechanism. 15, 16 The influence of diseases such as cancer, organ transplantation, and liver disease on in vivo CYP3A4 activity have been well documented in the literature. [17] [18] [19] [20] [21] [22] Interestingly, to our knowledge, in vivo human CYP3A4 activity has only been reported in one other study in the setting of IBD. This study limited its evaluation of CYP3A4 activity to single-point determination of 4b-hydroxycholesterol (4b-OHC) plasma concentrations, which has certain limitations. 23 Human in vivo P-gp activity has not been assessed in the setting of IBD.
Furthermore, the glucocorticoid, budesonide, an important part of IBD therapy for individuals with ileal CD, shows varying efficacy in this population. It is a known substrate of CYP3A4 and has been shown, at least in vitro, to be a substrate of P-gp. 9, 24 Rates of remission in the largest clinical trials involving budesonide tend to be approximately 50%, leaving the other 50% of the cohort with partially or fully active disease. [25] [26] [27] There are limited budesonide pharmacokinetic (PK) data on CD; however, in a single budesonide PK study in a cohort of adult CD subjects and in healthy populations, budesonide exposure after oral administration was noted to be highly variable. 2, 28, 29 This variability in budesonide exposure may be due to interindividual differences in total CYP3A4 and P-gp activity. Moreover, it may account for some of the discordance seen in the rates of remission in individuals with IBD, specifically due to differences in intestinal CYP3A4 and P-gp.
Accordingly, we sought to assess the relative contribution of CYP3A4 versus P-gp in CD to drug metabolism using well known in vivo probes fexofenadine (P-gp probe), 30 midazolam (CYP3A4 probe), 31 and budesonide as a putative shared probe substrate of both CYP3A4 and P-gp among CD subjects who are on stable dose of budesonide for therapeutic benefit.
METHODS

Subjects
The study protocol was approved by the University of Western Ontario Health Sciences Research Ethics Board (104914). (see Fig. S1 , Supplemental Digital Content 1, http:// links.lww.com/IBD/B468, summarizes the study protocol). Written informed consent was obtained from each patient. Patient recruitment took place from March 2014 to September 2014. Eligible subjects were aged 18 years or older with a history of CD who were starting on or currently taking the oral medication, budesonide. Subjects receiving concurrent medical treatment for their CD (n ¼ 8) were eligible for this study. Subjects were excluded from the study for the following reasons: having a hypersensitivity to budesonide; having a hypersensitivity to midazolam; having a hypersensitivity to fexofenadine; having a serum creatinine concentration greater than 1.7 mg per deciliter; being pregnant or breastfeeding; having a preexisting liver disease (examples include primary sclerosing cholangitis, autoimmune hepatitis, alcoholic liver disease, viral hepatitis, and cirrhosis); taking other concurrent benzodiazepines; being unwilling to comply with the study protocol; having an estimated survival of less than 1 year; abusing or misusing alcohol; being an active smoker; and receiving ongoing therapy or treatment in the last 3 months with drugs known to be potent CYP3A inhibitors or inducers. These are as follows: macrolide antibiotics, "azole" antifungals, nefazodone, verapamil, diltiazem, cyclosporine A, antiretrovirals, carbamazepine, phenytoin, lamotrigine, rifampin, rifabutin, dexamethasone, St. John's Wort, and bosentan. Subjects were screened for eligibility 4 weeks before enrollment. Body weight and routine blood tests (blood count, biochemistries, liver enzymes, and creatinine) were measured for each patient. All female subjects were screened for pregnancy with a urine pregnancy test. At baseline, demographic data, including age, sex, year of CD diagnosis, disease distribution, and current medications were collected from each patient. Clinical parameters to assess for disease activity (Harvey-Bradshaw index), and subjective response to budesonide, including efficacy and toxicity were noted.
Subjects were instructed to avoid citrus fruit products for 1 week before their study day because of the inhibitory effect on CYP3A4 activity. They were also instructed to avoid alcohol or caffeine 1 day before their study day. Subjects were instructed to take nothing by mouth the morning of their study day. At the start of each study day (time 0), subjects were administered an oral dose of budesonide (3-9 mg). The dose of budesonide was chosen based on the standard practice of care carried out at London Health Sciences Centre for inducing remission in individuals with CD. Subjects were also given a 180-mg dose of oral fexofenadine hydrochloride and a prepared 100 mg dose of oral midazolam. At the 8-hour time interval, subjects were given a prepared 50 mg dose of intravenous (IV) midazolam. The dose of oral fexofenadine hydrochloride and oral and IV midazolam were selected based on previous studies conducted to assess the in vivo activity of CYP3A4 and P-gp. [30] [31] [32] [33] [34] Blood samples were collected from each subject at 19 prespecified time points measured in hours (0, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 8.08, 8.25, 8.5, 9, 9.5, 10, 11, and 12). Samples were spun down using a centrifuge, and plasma was extracted and stored at 2808C.
Quantitation of Budesonide, Fexofenadine, and Midazolam Plasma Concentrations
Midazolam plasma concentrations were determined by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) using a previously described method by Gong et.al 32 (2012) Supplemental Data. The lowest limit of quantification was 0.025 ng/mL.
For measuring budesonide, a 500-mL plasma sample was acidified using 50 mL 4% formic acid (diluted in water) containing the internal standard, d6-budesonide (10 mL, 500 ng/mL in methanol; Toronto Research Chemicals, Toronto, ON). Standards made with drug-free plasma were similarly spiked with budesonide internal standard as described above. Protein was precipitated from samples and standards with the addition of 500 mL of 30% ethanol in water and incubation at 48C for 15 minutes. Precipitated proteins were pelleted by centrifugation at 14,000g at 48C for 10 minutes. Supernatants were applied to OASIS HLB 96-well plates (5 mg/well, 30 mm particle size; Waters, Milford, MA) pretreated with 1 mL of methanol and water each. Wells were washed with 1 mL of 20% methanol and eluted using 0.5 mL of 100% methanol. The eluate was dried with heat (708C) and reconstituted using the mobile phase (150 mL of acetonitrile/ 5 mM ammonium acetate in water [25%/75%]). One hundred microliters of sample was injected into the liquid chromatograph (1200 Series; Agilent Technologies, San Jose, CA).
Analytes were separated using reverse phase chromatography on a Thermo Hypersil Gold C18 Column (50 · 5 mm; 5 mm) using gradient elution with mobile phase A (5 mM ammonium acetate in water) and mobile B phase (acetonitrile) over minutes: Fexofenadine plasma concentrations were measured using UPLC-MS/MS. Proteins were precipitated from the plasma by the addition of 150 mL acetonitrile containing the internal standard, d6-fexofenadine (10 ng/mL; Toronto Research Chemicals, Toronto, ON), to 50 mL of sample. Standards made in drug-free plasma were diluted similarly with d6-fexofenadine in acetonitrile. Precipitated proteins were pelleted by centrifugation at 14,000 rpm at 48C for 10 minutes. One hundred fifty microliters of 0.1% formic acid in water was added to 50 mL of supernatant. Seventy-five microliters of the resultant solution for each sample was injected into the liquid chromatograph (Agilent 1200). Analytes were separated using reverse phase chromatography on a Thermo Hypersil Gold C18 Column (50 · 5 mm; 5 mm) using gradient elution with mobile phase A (0.1% formic acid in water) and mobile B phase Mass detection occurred on a Thermo TSQ Vantage triple quadrupole mass spectrometer, set in positive mode, with a quantitative and qualitative mass transition measured for fexofenadine HCL (502.2/466.5 m/z). The standard curves were linear over 0 to 500 ng/mL concentration range.
PK Analysis
PK analysis was performed by the noncompartmental method. PK parameters collected included the following: maximum plasma drug concentration (C max ); time to the maximum plasma drug concentration (t max ); total drug exposure estimated by the area of under the plasma concentration-time curve (AUC 0-N ); the drug half-life (t 1/2 ); and oral drug clearance (CL/ F). For midazolam, where IV and oral data were available, systemic drug clearance (CL s ), oral bioavailability (F), and estimates of CYP3A4-mediated hepatic and intestinal extraction ratios were calculated. PK parameters were calculated based on the concentration-time curve for each drug.
C max and t max were obtained by visual inspection. The AUC 0-N for each drug for each patient was calculated using the trapezoidal rule (numerical integration) to the last measured time point and extrapolating to infinity using the terminal elimination rate constant (k e ), estimated by log-linear regression of last 4 to 6 data points on the concentration-time curve. The t 1/2 was obtained by dividing the constant 0.693 by k e . Oral clearance of all 3 drugs was calculated as the ratio of the oral dose divided by the oral AUC 0-N .
For midazolam, F was calculated by dividing the product of the oral AUC 0-N and IV dose by the product of the IV AUC 0-N and oral dose. CYP3A4-mediated extraction in the liver and intestine were estimated by the hepatic and gut extraction ratios (E h and E gi ), where E h ¼ CL s /Q h, plasma and E gi 5 12½F=ð12Ε h Þ. Q h, plasma represented the liver plasma flow and was equal to (1 2 hematocrit) · Q h, blood . Q h, blood or liver blood flow was assumed to be 25.7 mL/min per kg of body weight.
Statistical Analysis
Data are presented as the arithmetic mean with SDs. Interpatient budesonide plasma concentrations were compared using unpaired t tests. Linear regression analysis was used to assess the possible relationship between the PK values of budesonide and each of midazolam and fexofenadine. All statistical analyses were preformed in Graphpad, Prism, and SPSS.
RESULTS
Subjects with CD
Seven females and 1 male completed the study protocol. The demographic data and clinical characteristics for each subject are presented in Table 1 . There were no adverse events. All subjects were on budesonide therapy for a minimum of 1 month before entry into the study. All subjects had not received treatment with a CYP3A4-inhibiting or -inducing drug in at least 1 year.
PK Assessment
The PK parameters for budesonide, fexofenadine, and IV and oral midazolam are presented in Table 2 . Budesonide values are standardized to a 1-mg dose. Mean plasma concentration-time curves for budesonide, fexofenadine, and IV and oral midazolam are shown in Figure 1A -C. Budesonide plasma concentration-time curves for individual subjects are shown in Figure 2A , B. Panel A illustrates the budesonide plasma concentration-time curves standardized to a 1-mg dose, and panel B illustrates the budesonide plasma concentration-time curves color coded by dose. There was significant interpatient variability in budesonide exposure ( Fig. 2A, B) (coefficient of variation ¼ 0.626; P , 0.001).
An individual's exposure to a drug is represented by the area under concentration versus time curve extrapolated to infinity (AUC 0-N ). The mean oral AUC 0-N of budesonide, fexofenadine, and midazolam were 2.02 ng/mL$h 6 1.25, 2199.4 ng/mL$h 6 766.68, and 4.57 ng/mL$h 6 2.08, respectively (see Tables   S1-S3 , Supplemental Digital Content 1, http://links.lww.com/ IBD/B468). Mean oral clearance (CL/F) was 32,347.5 mL/min 6 12,617.6 (budesonide), 1507.89 mL/min 6 513.4 (fexofenadine HCL), and 437.9 mL/min 6 218.6 (midazolam). The systemic clearance (Cl s ) of midazolam was 117.1 mL/min 6 71.8 (Table 2) .
Comparison Between Drugs
The mean hepatic and intestinal extraction ratios for midazolam representing the proportion of CYP3A4 activity occurring were 0.11 6 0.06 and 0.64 6 0.25, respectively (Fig.  3A, B) . The mean oral bioavailability (F) of midazolam was 31% 6 22% (Fig. 3C ). There was no significant relationship between budesonide exposure (AUC 0-N ) and the oral clearances or exposures of fexofenadine or midazolam (see Fig. S2 , panel A-D, Supplemental Digital Content 1, http://links.lww.com/IBD/ B468). Multivariate regression analysis of budesonide exposure revealed that 25% of a subject's exposure was dependent on fexofenadine or midazolam oral clearance.
DISCUSSION
CYP3A4 and P-gp are considered to be the most clinically relevant determinants of drugs in clinical use today. Although there is a significant amount of data in terms of CYP3A4 and P-gp activity in vivo in human subjects, nearly all such studies have been conducted in healthy volunteers. In disease conditions such IBD, remarkably little is known regarding the extent of CYP3A4 or P-gp activity. In this study, we studied subjects with active CD on stable doses of the glucocorticoid drug, budesonide, where PK analysis of multiple probe substrates of CYP3A4 and P-gp were used to better delineate the difference in hepatic versus intestinal CYP3A4, as well as P-gp activity. To our knowledge, this is the first study to assess CYP3A4 and P-gp activity in a CD population using the in vivo probes midazolam and fexofenadine.
In this study, we note that subjects with CD have a comparable exposure to budesonide, a drug known to be metabolized by CYP3A4 and transported in vitro by P-gp, to what has been reported in studies of healthy individuals when standardized to the same dose (Fig. 4A , see Table S1 , Supplemental Digital Content 1, http://links.lww.com/IBD/B468). 2, 28, 35 We also see that budesonide exposure is highly variable in subjects with CD ( Fig. 2A, B) , consistent with that shown in healthy populations and in an adult CD population. 2, 29 This may account for the some of the variability seen in response to budesonide treatment. A proportional reduction in the Harvey-Bradshaw index, a clinical scale of disease activity in CD, was seen with increasing budesonide plasma concentrations (see Fig. S3 , Supplemental Digital Content 1, http://links.lww. com/IBD/B468); however, the sample size from our study was too small to draw any firm conclusions, although it did achieve statistical significance (P ¼ 0.012).
In our study, only 25% of the variability in budesonide exposure can be predicted by CYP3A4 and P-gp activity. This suggests that there are other factors determining budesonide exposure in CD, and that CYP3A4 and P-gp did not have a significant impact on its disposition in this population.
One aspect of our findings that is of potential clinical relevance is the near 5-fold higher AUC 0-N for oral midazolam in our patient population compared with what has been reported in healthy populations ( Fig. 4B and see Table S3 , Supplemental Digital Content 1, http://links.lww.com/IBD/B468). 31, 32, 37, 38 This suggests that total CYP3A4 activity is more profoundly reduced in CD compared with healthy individuals. Interestingly, the decrease in CYP3A4 activity cannot necessarily be attributed to a reduction in intestinal CYP3A4 activity, as one might suspect in a primary intestinal illness. A higher degree of midazolam extraction and subsequently CYP3A4 activity occurred in the gut (E gi ¼ 0.64 6 0.25) compared with the liver (E h ¼ 0.11 6 0.06) (Fig.  3A, B) . And although, to date, the degree of extraction in the liver versus the intestine has been reported at varying levels, the degree of difference seen between the liver and gut extraction in our CD population has not been seen in healthy populations. 33, [38] [39] [40] One potential limitation of our current study might be the absence of a control population. However, in comparison to a cohort of healthy volunteers who participated in a previous study conducted in our laboratory 32 using the same midazolam microdose-based phenotyping approach for CYP3A4 and the same LC MS/MS assay used in this study, we observed a marked reduction in CD subjects (Fig. 4B and see Table S3 , Supplemental Digital Content 1, http://links.lww.com/IBD/B468).
Reduced hepatic CYP3A4 activity in the setting of systemic or nonhepatic inflammation has been reported, although our study is the first to demonstrate such an effect in IBD using midazolam microdosing. In vitro and in vivo animal studies both conclusively show that in the setting of acute nonhepatic inflammation, hepatic CYP3A4 expression is downregulated. 41 Studies in humans show an increase in the plasma drug concentrations of CYP3A4 substrates in the setting of acute inflammation. 42 Hepatic CYP3A4 has been shown to be downregulated because of the effects of interleukin-1b, interleukin-6, tumor necrosis factor alpha, and interferon-a and g. 41, 43 The effect of chronic inflammation on intestinal CYP3A4 activity and expression in humans is not well defined, and there is a paucity of literature on this subject. As a means of assessing CYP3A4 activity in IBD, Iwamoto et al (2013) evaluated single-point 4b-OHC plasma concentrations in subjects with IBD and healthy volunteers. The evaluation of hepatic CYP3A activity using the endogenous marker, 4b-OHC, has been well documented. 44 CYP3A4 and 3A5 regulate the production of 4b-OHC, and it is useful for the evaluation of CYP3A induction by specific drugs; however, there are limitations to its accuracy. Only a weak correlation was found between midazolam PK parameters (total and liver CYP3A4 activity) and 4b-OHC plasma concentrations. 45 The authors suggest that this may be partially explained by the fact that 4b-OHC is a substrate of both CYP3A4 and 3A5, whereas midazolam is only a substrate of CYP3A4. 44 Furthermore, 4b-OHC is a measure of hepatic CY-P3A4 activity but has not been evaluated for assessing intestinal CYP3A4 contributions. 46, 47 Moreover, 4b-OHC has a long halflife (1-3 wk) and therefore cannot be used to assess rapid fluctuations in CYP3A activity. 44, 45 It was concluded that 4b-OHC may be most useful for assessing induction rather than inhibition or constitutive CYP3A4 activity. Midazolam PK parameters are currently viewed as the gold standard for assessing CYP3A4 activity in vivo. 44 P-gp expression has been shown to be decreased in the setting of intestinal inflammation in in vivo models and in multiple small IBD cohort studies. [48] [49] [50] [51] It has been suggested that loss of expression may be due to disruption of the integrity of the enterocyte apical membrane by inflammatory cytokines. We found that that the mean ORAL AUC 0-N and C max of fexofenadine were reduced in our CD cohort compared with what has been reported in the literature among healthy volunteers, although its activity is quite variable even among healthy cohorts ( Fig. 4C and see Table S2 , Supplemental Digital Content 1, http://links.lww. com/IBD/B468). [52] [53] [54] Lower fexofenadine exposure, if solely dependent on P-gp would mean that P-gp expression is greater in IBD compared with healthy subjects. However, fexofenadine is also a substrate of various OATP families of uptake transporters, and because OATP2B1 tends to be abundantly expressed in the intestine, reduced fexofenadine exposure may have resulted from reduced intestinal OATP expression.
We do note that one limitation of this study was the relatively small sample size, therefore reducing the generalizability of our study to the larger CD population. Sample size was hampered by the intensiveness of the study protocol and the intrinsic difficulties of conducting clinical studies among subjects with an active disease. The strength of the study, however, is the detailed PK analysis over 12 hours, where multiple in vivo probe medications were assessed simultaneously. Another possible confounder included the study subjects' exposure to budesonide before participating the PK study day. Budesonide exposure induces a modest increase in CYP3A4 gene expression in vivo. 55 However, our current findings of lower midazolam clearance in our CD population compared with published data among healthy subjects would suggest overall CYP3A4 phenotype is that of reduced expression or function rather than induction. In addition, there are contradictory reports of the impact of budesonide exposure on PXR-mediated expression of P-gp in vitro. 56 
CONCLUSIONS
In summary, this is the first study in a CD population evaluating CYP3A4 and P-gp in vivo activity. Both CYP3A4 and P-gp activity were lower in the setting of CD, although CYP3A4 was more profoundly affected. Interestingly, this effect was mainly because of a reduction in hepatic CYP3A4 activity. Our findings suggest that a disease-dependent reduction in CYP3A4 needs to be taken into consideration when prescribing substrate drugs such as certain HMG-CoA reductase inhibitors, benzodiazepines, or oral anticoagulants to a CD population, especially substrate drugs with a narrow therapeutic index. Clinically, this would indicate that a CYP3A4 substrate dose reduction may be necessary in this population, although further studies are needed.
